Literature DB >> 22547217

Haematological cancer: Gemtuzumab ozogamicin in acute myeloid leukaemia.

Farhad Ravandi, Hagop Kantarjian.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22547217     DOI： 10.1038/nrclinonc.2012.83

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  6 in total

Review 1.  High-dose cytosine arabinoside in the treatment of acute myeloid leukemia: Review of three randomized trials.

Authors:  Wolfgang Kern; Elihu H Estey
Journal:  Cancer       Date:  2006-07-01       Impact factor: 6.860

2.  Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.

Authors:  Alan K Burnett; Robert K Hills; Donald Milligan; Lars Kjeldsen; Jonathan Kell; Nigel H Russell; John A L Yin; Ann Hunter; Anthony H Goldstone; Keith Wheatley
Journal:  J Clin Oncol       Date:  2010-12-20       Impact factor: 44.544

3.  Cytarabine dose for acute myeloid leukemia.

Authors:  Bob Löwenberg; Thomas Pabst; Edo Vellenga; Wim van Putten; Harry C Schouten; Carlos Graux; Augustin Ferrant; Pieter Sonneveld; Bart J Biemond; Alois Gratwohl; Georgine E de Greef; Leo F Verdonck; Martijn R Schaafsma; Michael Gregor; Matthias Theobald; Urs Schanz; Johan Maertens; Gert J Ossenkoppele
Journal:  N Engl J Med       Date:  2011-03-17       Impact factor: 91.245

4.  Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.

Authors:  Sylvie Castaigne; Cécile Pautas; Christine Terré; Emmanuel Raffoux; Dominique Bordessoule; Jean-Noel Bastie; Ollivier Legrand; Xavier Thomas; Pascal Turlure; Oumedaly Reman; Thierry de Revel; Lauris Gastaud; Noémie de Gunzburg; Nathalie Contentin; Estelle Henry; Jean-Pierre Marolleau; Ahmad Aljijakli; Philippe Rousselot; Pierre Fenaux; Claude Preudhomme; Sylvie Chevret; Hervé Dombret
Journal:  Lancet       Date:  2012-04-05       Impact factor: 79.321

5.  Anthracycline dose intensification in acute myeloid leukemia.

Authors:  Hugo F Fernandez; Zhuoxin Sun; Xiaopan Yao; Mark R Litzow; Selina M Luger; Elisabeth M Paietta; Janis Racevskis; Gordon W Dewald; Rhett P Ketterling; John M Bennett; Jacob M Rowe; Hillard M Lazarus; Martin S Tallman
Journal:  N Engl J Med       Date:  2009-09-24       Impact factor: 91.245

6.  Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype.

Authors:  C D Bloomfield; D Lawrence; J C Byrd; A Carroll; M J Pettenati; R Tantravahi; S R Patil; F R Davey; D T Berg; C A Schiffer; D C Arthur; R J Mayer
Journal:  Cancer Res       Date:  1998-09-15       Impact factor: 12.701
  6 in total
  3 in total

Review 1.  Biological agents: what they are, how they affect oral health and how they can modulate oral healthcare.

Authors:  E Georgakopoulou; C Scully
Journal:  Br Dent J       Date:  2015-07       Impact factor: 1.626

Review 2.  Frontline treatment of acute myeloid leukemia in adults.

Authors:  Gevorg Tamamyan; Tapan Kadia; Farhad Ravandi; Gautam Borthakur; Jorge Cortes; Elias Jabbour; Naval Daver; Maro Ohanian; Hagop Kantarjian; Marina Konopleva
Journal:  Crit Rev Oncol Hematol       Date:  2016-12-11       Impact factor: 6.312

3.  Gemtuzumab ozogamicin can reduce minimal residual disease in patients with childhood acute myeloid leukemia.

Authors:  Carol O'Hear; Hiroto Inaba; Stanley Pounds; Lei Shi; Gary Dahl; W Paul Bowman; Jeffrey W Taub; Ching-Hon Pui; Raul C Ribeiro; Elaine Coustan-Smith; Dario Campana; Jeffrey E Rubnitz
Journal:  Cancer       Date:  2013-09-04       Impact factor: 6.860
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.